Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement

4/17/24 8:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ELAN alert in real time by email

GREENFIELD, Ind., April 17, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE:ELAN) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance.

The conference call will begin at 8:00 a.m. eastern time. Investors, media, and the general public can access a live webcast of the conference call through the link that will be posted on Elanco's website at https://investor.elanco.com/events-and-presentations/default.aspx. A replay will also be available on the website shortly following the call.

ABOUT ELANCO

Elanco Animal Health Incorporated (NYSE:ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability Initiatives – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.

Investor Contact: Katy Grissom +1.317.273.9284 [email protected]

Media Contact: Colleen Parr Dekker +1.317.989.7011 [email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/elanco-confirms-date-and-conference-call-for-first-quarter-2024-financial-results-announcement-302118741.html

SOURCE Elanco Animal Health

Get the next $ELAN alert in real time by email

Recent Analyst Ratings for

$ELAN

Date	Price Target	Rating	Analyst
12/9/2024	$18.00	Buy	UBS
12/2/2024	$14.00	Market Perform	Leerink Partners
9/19/2024	$17.00 → $15.00	Overweight → Equal-Weight	Morgan Stanley
1/5/2024	$13.00 → $20.00	Hold → Buy	Stifel
12/19/2023	$17.00	Buy	Jefferies
12/15/2023	$16.00	Equal-Weight → Overweight	Morgan Stanley
12/7/2023	$18.00	Outperform	Exane BNP Paribas
4/20/2023	$14.00	Equal Weight → Overweight	Barclays

More analyst ratings

Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement

Chat with this insight

Recent Analyst Ratings for
$ELAN

$ELAN
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

$ELAN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

UBS initiated coverage on Elanco Animal Health with a new price target

Leerink Partners initiated coverage on Elanco Animal Health with a new price target

Elanco Animal Health downgraded by Morgan Stanley with a new price target

$ELAN
SEC Filings

SEC Form SD filed by Elanco Animal Health Incorporated

Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Elanco Animal Health Incorporated

$ELAN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Modi Rajeev A.

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

Elanco Confirms Date and Conference Call for First Quarter 2024 Financial Results Announcement

Chat with this insight

Recent Analyst Ratings for $ELAN

$ELAN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Kurzius Lawrence Erik bought $211,000 worth of shares (20,000 units at $10.55), increasing direct ownership by 22% to 111,459 units (SEC Form 4)

Director Hoover R David bought $272,558 worth of shares (25,000 units at $10.90) (SEC Form 4)

Director Harrington Michael J bought $51,974 worth of shares (3,500 units at $14.85), increasing direct ownership by 5% to 81,094 units (SEC Form 4)

$ELAN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

UBS initiated coverage on Elanco Animal Health with a new price target

Leerink Partners initiated coverage on Elanco Animal Health with a new price target

Elanco Animal Health downgraded by Morgan Stanley with a new price target

$ELAN SEC Filings

SEC Form SD filed by Elanco Animal Health Incorporated

Elanco Animal Health Incorporated filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form 10-Q filed by Elanco Animal Health Incorporated

$ELAN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Modi Rajeev A.

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N

Recent Analyst Ratings for
$ELAN

$ELAN
Insider Purchases

$ELAN
Analyst Ratings

$ELAN
SEC Filings

$ELAN
Insider Trading